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Abstract—Previous studies have found pulse pressure (PP), a marker of arterial stiffness, to be an independent predictor of atrial
fibrillation (AF) in general and hypertensive populations. We examined whether PP predicted new-onset AF in comparison
with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a
double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and
electrocardiographic left ventricular hypertrophy. In 8810 patients with neither a history of AF nor AF at baseline, Minnesota
coding of electrocardiograms confirmed new-onset AF in 353 patients (4.0%) during mean 4.9 years of follow-up. In
multivariate Cox regression analyses, baseline and in-treatment PP and baseline and in-treatment systolic blood pressure
predicted new-onset AF, independent of baseline age, height, weight, and Framingham Risk Score; sex, race, and treatment
allocation; and in-treatment heart rate and Cornell product. PP was the strongest single blood pressure predictor of new-onset
AF determined by the decrease in the2 Log likelihood statistic, in comparison with systolic blood pressure, diastolic blood
pressure, and mean arterial pressure. When evaluated in the same model, the predictive effect of systolic and diastolic blood
pressures together was similar to that of PP. In this population of patients with hypertension and left ventricular hypertrophy,
PP was the strongest single blood pressure predictor of new-onset AF, independent of other risk factors. (Hypertension. 2012;
60:347-353.) ● Online Data Supplement
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Atrial fibrillation (AF) is the most prevalent sustainedcardiac arrhythmia, and the prevalence is increasing.1 In
the Rotterdam study, the prevalence of AF varied from 0.7%
in the age group 55 to 59 years to 17.8% in those aged 85
years.2 AF incidence increases with age,3 and other risk
factors include diabetes, obesity, hypertension, left ventricu-
lar hypertrophy (LVH), coronary heart disease, congestive
heart failure, valvular heart disease, and increased left atrial
size by echocardiography.4–6 AF is associated with a 4- to
5-fold increased risk of ischemic stroke7,8 and with a nearly
doubled cardiovascular mortality risk.9 Prevention of AF is
thus of great importance, and hypertension is currently the
most prevalent, potentially modifiable risk factor, accounting
for 14% to 22% of AF cases.4,10,11
Increased pulse pressure (PP), defined as the difference
between systolic blood pressure (SBP) and diastolic blood
pressure (DBP), is a marker of arterial stiffness.12 Studies
have found PP to be an independent predictor of new-onset
AF in both general13 and hypertensive14 populations. Mitch-
ell et al13 showed that increased baseline PP was the single
blood pressure (BP) component most predictive of AF in
5331 participants (23% on antihypertensive treatment;
1.2% with electrocardiograpic LVH [ECG-LVH]) during
20 years of follow-up in the Framingham Heart Study and
indicated that the relation between BP and incident AF is
potentially related, specifically, to the pulsatile component of
BP as assessed by PP. In a study by Ciaroni et al,14 increased
PP (measured by 24-hour ambulatory BP measurement)
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during antihypertensive treatment was associated with an
increased risk of new-onset AF, independent of age, sex,
body mass index, and SBP in 597 patients with essential
hypertension followed for 7 years. A pathophysiological
explanation may be that arterial stiffness increases with age,
resulting in increased PP and increased pulsatile load on the
heart,15 promoting LVH,16 left ventricular diastolic dysfunc-
tion,17,18 and increased left atrial size,19 possibly leading to
fibrosis and electric remodeling in the left atrium and,
eventually, AF. In a study by Goette et al,20 patients with
permanent AF had increased amount of atrial fibrosis; how-
ever, whether atrial fibrosis induces AF or is a consequence
of AF is still unknown.
To our knowledge, the relation between baseline PP and PP
during antihypertensive treatment and risk of new-onset AF
has not yet been evaluated in high-risk patients with hyper-
tension and ECG-LVH. Therefore, the goals of this prespeci-
fied Losartan Intervention For Endpoint (LIFE) reduction in
hypertension substudy were to investigate the predictive
value of higher baseline and in-treatment brachial PP for
new-onset AF in patients with hypertension and LVH and to
perform a thorough comparison of the predictive value of PP
to that of other BP components such as SBP, DBP, and mean
arterial pressure (MAP), using the Framingham study by
Mitchell et al as a model.13
Methods
Study Design and Population
The LIFE study21,22 enrolled 9193 patients with essential hyperten-
sion (mean sitting brachial BP: 160 to 200 mm Hg systolic, 95 to 115
mm Hg diastolic, or both) and ECG-LVH (determined by Cornell
voltage-duration product23,24 and/or Sokolow-Lyon voltage crite-
ria,25) randomized to losartan- versus atenolol-based therapy. (For
further details, please see http://hyper.ahajournals.org.) New-onset
AF was a prespecified secondary end point. The present analyses
included 8810 patients with neither a history of AF nor AF on their
baseline ECG. New-onset AF was identified by Minnesota coding of
annual in-study ECGs at the core laboratory at Sahlgrenska Univer-
sity Hospital/Östra, Göteborg, Sweden.21,26
Statistical Analyses
Statistical analyses were performed by the investigators using SPSS
version 16.0 (SPSS Inc). Data are presented as meanstandard
deviation (SD) for continuous variables and as proportions for
categorical variables. Brachial PP was calculated as the difference
between SBP and DBP. MAP was calculated as DBP plus one third
of PP. Baseline characteristics in patients grouped according to
quartiles of baseline PP were compared using analysis of variance
(ANOVA) for continuous variables and Pearson 2 statistics for
categorical variables. Annual measurements of mean PP, SBP, DBP,
and MAP were compared using general linear models to account for
the within-subject correlation. The incidence of new-onset AF
according to quartiles of baseline PP was illustrated in an unadjusted
Kaplan-Meier curve.
In the primary analyses, possible associations between baseline PP
or PP during antihypertensive therapy and the risk of developing
new-onset AF were analyzed using Cox proportional hazards regres-
sion analyses.27,28 Baseline PP was entered as a continuous covari-
ate, and in-treatment PP (baseline and subsequent routine measure-
ments of PP during follow-up) was entered as a time-varying
continuous covariate into univariate and multivariate Cox regression
models. Additional covariates in the multivariate model were se-
lected based on being significant univariate predictors that continued
to be significant predictors in stepwise forward and backward
multivariate analyses.
In the secondary analyses, we explored the relations between
different BP components (PP, SBP, DBP, and MAP) as baseline and
time-varying covariates and new-onset AF using the same multivar-
iate Cox regression model and including a single BP component (PP,
SBP, DBP, or MAP) or a combination of BP components (SBP and
DBP, or PP and MAP). Hazard ratios (HR) for the incidence of
new-onset AF associated with baseline and in-treatment PP, SBP,
DBP, and MAP were computed per 1 SD of the baseline mean and
per 10 mm Hg increments in BP.29,30 Wald 2 statistics and P values
were calculated. The decrease in the 2 Log likelihood statistic (a
measure of model fit with data), caused by adding a single BP
component (degrees of freedom [df]1) or a combination of BP
components (df equals the number of covariates added to the model)
to the multivariate Cox regression model and 2 tests, were used to
evaluate and compare the relative importance and predictive effects
of PP, SBP, DBP, and MAP. In addition, PP was also evaluated as
a categorical variable with quartiles of baseline PP in multivariate
analyses. Interaction analyses were performed using Cox regression
models with 2 and 2 covariates and their cross-products.
Possible correlations between BP components were analyzed
using Pearson correlation coefficient. A 2-tailed P0.05 was re-
quired for statistical significance. All study data reside in a database
with the authors.
Results
Patient Population and Blood Pressures
In 8810 patients (46% men) at risk of developing new-onset
AF, mean baseline PP was 76.515.5 mm Hg (74.615.6
mm Hg for men and 78.015.3 mm Hg for women), with a
range of 23.5 to 134.0 mm Hg. Mean age at randomization
was 65.96.9 years for men and 67.57.0 years for women.
Elevated PP 60 mm Hg at baseline was recorded in 7623
(86.5%) patients. Clinical characteristics according to quar-
tiles of baseline PP (67.0 mm Hg, 67.5 to 77.0 mm Hg, 77.5
to 87.0 mm Hg, and 87.5 mm Hg) are presented in Tables
1 and online-only Data Supplement S1 (see http://hyper.
ahajournals.org).
Mean BP values at baseline and during follow-up are
displayed in Figure 1. At baseline, mean SBP was
174.314.3 mm Hg, mean DBP was 97.98.8 mm Hg, and
average MAP was 123.38.1 mm Hg. In patients followed
for at least 4 years, 41.3% had a reduction in PP 15.5
mm Hg (1 SD of the baseline mean), 79.8% had a reduction
in SBP 14.3 mm Hg (1 SD), 80.2% had a reduction in DBP
8.8 mm Hg (1 SD), and 87.8% had a reduction in MAP
8.1 mm Hg (1 SD).
Baseline PP was strongly correlated with SBP (Pearson
correlation coefficient [r]0.83; P0.001), moderately cor-
related with DBP (r0.41; P0.001), and more weakly
correlated with MAP (r0.19; P0.001). Baseline MAP was
strongly correlated with SBP (r0.71; P0.001) and DBP
(r0.82; P0.001). There was a relatively weak correlation
between baseline SBP and DBP (r0.17; P0.001).
Multivariate Cox Regression Analyses
ECG confirmed new-onset AF in 353 (4.0%) of 8810 patients
during a mean follow-up of 4.90.9 years. Figures 2 and 3
present the incidence of AF by quartiles of baseline PP.
Results of the multivariate Cox regression model examin-
ing the predictive effect of baseline and in-treatment PP for
new-onset AF are presented in Model 2 of Table 2 and in
Table S2 (see http://hyper.ahajournals.org). Baseline PP was
associated with a 39% (95% confidence interval [CI], 22% to
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58%; P0.001) increased risk of new-onset AF per 15.5
mm Hg (SD) increase, and in-treatment PP was associated
with a 33% (95% CI, 18% to 50%; P0.001) increased risk
of new-onset AF per SD increase in a model adjusting for
baseline age, height, weight, and Framingham Risk Score
(FRS); sex, race, and a treatment group indicator (atenolol
versus losartan), entered as continuous or categorical covari-
ates; and in-treatment heart rate and ECG-LVH by Cornell
product, entered as time-varying continuous covariates. Sex
was a significant univariate predictor and was included in the
multivariate Cox regression model for biological reasons,
even though it was not significant in multivariate analyses.
Smoking, diabetes, previous myocardial infarction, and body
mass index did not predict new-onset AF; however, replacing
height and weight with body mass index in the multivariate
model did not alter the results. Baseline total cholesterol,
potassium, and urine albumin-creatinine ratio were signifi-
Table 1. Baseline Characteristics by Quartiles of Baseline PP (n8810)*
Characteristics
Q1 (67.0 mm Hg)
n2334
Q2 (67.5–77.0 mm Hg)
n2189
Q3 (77.5–87.0 mm Hg)
n2139
Q4 (87.5 mm Hg)
n2148 P Value
Male sex, n (%) 1234 (53) 1019 (47) 928 (43) 833 (39) ‡
Age, y 647 667 687 706 †
White race, n (%) 2115 (91) 2016 (92) 1998 (93) 2013 (94) ‡
Weight, kg 8115 7915 7816 7614 †
Height, cm 16910 1689 1679 1669 †
BMI, kg/m2 28.24.7 28.04.8 28.25.1 27.74.6 †
History of diabetes, n (%) 213 (9) 235 (11) 296 (14) 359 (17) ‡
History of CHD, n (%) 268 (12) 293 (13) 276 (13) 322 (15) ‡
SBP, mm Hg 15910 1717 1799 18910 †
DBP, mm Hg 1026 997 979 9310 †
PP, mm Hg 578 723 823 967 NA
MAP, mm Hg 1216 1237 1259 1259 †
Heart rate, bpm 7511 7411 7411 7311 †
Cornell product, mmmsec 2738910 28281093 28491037 28511021 †
Total cholesterol, mmol/L 5.991.13 6.061.10 6.091.12 6.091.13 †
UACR, mg/mmol 5.730.7 5.620.7 7.329.1 9.835.5 †
FRS 208 229 2310 2510 †
*Values are meanSD or numbers (n) and percentages.
†P0.01 (analysis of variance).
‡P0.01 (Pearson 2).
PP indicates pulse pressure; y, years; BMI, body mass index; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean
arterial pressure; NA, not applicable; bpm, beats per minute; UACR, urine albumin-creatinine ratio; FRS, Framingham Risk Score.
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Figure 1. Mean blood pressure during 4.9 years of follow-up.
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cant univariate predictors and were significant in the multi-
variate model; however, the model did not change when these
covariates were excluded. Cox proportional hazards models
for PP in comparison with other BP components are pre-
sented in Table 2. All 10 models were adjusted for baseline
age, height, weight, and FRS; sex, race and treatment alloca-
tion; and in-treatment heart rate and ECG-LVH by Cornell
product. When comparing single BP components in parallel
multivariate models, adjusting for the same covariates, base-
line and in-treatment PP (Models 1 and 2) and baseline and
in-treatment SBP (Models 3 and 4), in addition to in-
treatment MAP adjusted for baseline MAP (Model 8), were
significant independent predictors of new-onset AF. Baseline
and in-treatment DBP were not significant predictors (Models
5 and 6). The initial 2 Log likelihood was 5773.6 for the
multivariate model, with baseline age, height, weight, and
FRS; sex, race, and treatment allocation; and in-treatment
heart rate and ECG-LVH by Cornell product. This model was
used as a basis to evaluate decrease in 2 Log likelihood
when introducing BP measures. Baseline and in-treatment PP
(Model 2) were the strongest single component predictors
(2 Log likelihood 5739.6; 234.0; 2 df, P0.001); how-
ever, when entering baseline and in-treatment SBP and DBP
into 1 model (Model 9), the model fit was equally good as for
the baseline and in-treatment PP model: 2 Log likelihood
5739.4 (234.2; df4; P0.001) compared with 5739.6.
The model with baseline and in-treatment SBP alone (Model
4) had a 2 Log likelihood of 5750.2, and adding baseline
and in-treatment DBP to the model (Model 9) thus induced a
significant improvement (210.8; df2; P0.01). In model
9, baseline and in-treatment SBP and DBP were all signifi-
cant predictors of new-onset AF; however, the effects of SBP
and DBP were opposite. Adding baseline and in-treatment
MAP to the model with baseline and in-treatment PP did not
change the model fit (2 Log likelihood 5739.4 for Model 10
and 5739.6 for Model 2), and baseline and in-treatment MAP
were not significant predictors in this model. When forcing
baseline and in-treatment PP, SBP, and DBP into the same
model, the HRs for DBP were not calculated owing to excess
colinearity (r1.0) with PP and SBP. In the same model,
baseline PP had a higher 2 (Wald score) than baseline SBP
(2 8.7 versus 0.01), and in-treatment PP was a stronger
predictor than in-treatment SBP (2 7.2 versus 0.08).
PP was also computed as a categorical variable, with
quartiles of baseline PP (quartile 4 versus quartiles 1 to 3).
When adjusted for baseline age, height, weight, and FRS; sex,
race, and treatment allocation; and in-treatment heart rate and
ECG-LVH by Cornell product, baseline PP quartile 4 (87.5
mm Hg) was associated with a 67% (95% CI, 32% to 211%;
P0.001) higher risk of new-onset AF compared with
quartiles 1 to 3. This result was strengthened when we also
adjusted for in-treatment PP in the same model (HR, 1.98;
95% CI, 1.55 to 2.52; P0.001).
There were no significant interactions between baseline or
in-treatment PP and other BP components or between base-
line or in-treatment PP and baseline age, height, weight, and
FRS; sex, race, and treatment allocation; and in-treatment
heart rate and ECG-LVH by Cornell product. There were
significant interactions between in-treatment heart rate and
weight (P0.03) and in-treatment heart rate and race
(P0.003) in all 10 models (Table 2). In model 9, there were
significant interactions between weight and in-treatment SBP
(P0.03) and weight and in-treatment DBP (P0.01). In
model 10, there were significant interactions between age and
in-treatment MAP (P0.02) and weight and in-treatment
MAP (P0.004).
Discussion
In the present study, increased baseline PP and PP during
antihypertensive treatment were associated with an increased
risk of incident AF, independent of other predictors of AF in
this population (ie, baseline age, height, weight, and FRS;
sex, race, and treatment allocation; and in-treatment heart rate
and ECG-LVH by Cornell product). Baseline PP quartile 4
(87.5 mm Hg) was associated with a highly significant
increase in risk of developing AF during mean 4.9 years of
follow-up compared with quartiles 1 to 3.
In comparison with SBP, DBP, and MAP as single BP
components, PP was the strongest predictor of incident AF.
When we considered the predictive effect of SBP and DBP
together, model fit improved significantly and had the same
2 Log likelihood as the PP model. This is a consequence of
the mathematical calculation of PP as the difference between
SBP and DBP. When evaluated in the same model, the effects
of SBP and DBP were significant but opposite, suggesting
that, for a certain value of SBP, lower DBP was associated
with an increased risk of new-onset AF. When evaluating PP,
SBP, and DBP in the same model, both baseline and
in-treatment PP had higher 2 (Wald score) than SBP. This
supports the finding that PP is the strongest single BP
measure for predicting incident AF in our study; however,
it should be interpreted with caution, considering the high
correlations between the BP components in this specific
model.
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In-treatment MAP was associated with incident AF when
adjusted for baseline MAP and the above-mentioned AF risk
factors. Entering MAP into the same model as PP did not
improve model fit; baseline and in-treatment MAP were not
significant, and the HRs of baseline and in-treatment PP were
unaltered. Thus, PP predicted incident AF independent of
MAP.
AF is associated with increased risk of cardiovascular
morbidity and mortality. It is highly important to identify
modifiable risk factors, as both men and women have an
approximate 25% overall lifetime risk of AF.31 To our
knowledge, this is the first study to report a strong, indepen-
dent association between brachial PP and new-onset AF in
patients with hypertension and ECG-LVH. Our results are in
agreement with a Framingham Heart Study investigation
evaluating PP as a predictor for incident AF in a general
population with normal or moderately increased BP.13 Fur-
thermore, Mitchell et al demonstrated that there is a potential
weakness of concentrating on SBP alone and ignoring DBP
and PP, and our data support this finding. When evaluating
the risk of incident AF in a hypertensive population with
ECG-LVH, PP should be considered or, alternatively, SBP
and DBP together. PP is simple to calculate as the absolute
difference between SBP and DBP.
Increased PP, a marker of advanced vascular aging32 and
arterial stiffness,12,33 may contribute in the structural and
electric remodeling of the myocardium, leading to the devel-
opment of AF, possibly through increased pulsatile load on
the heart and increased left atrial size.19 Studies have shown
that reduced distensibility of large arteries parallel cardiac
hypertrophy and remodeling in patients with hyperten-
sion.34,35 Large artery stiffness may increase the workload on
the heart similar to volume overload and, perhaps, represent
one of the mechanisms by which hypertension leads to
eccentric hypertrophy and left atrial enlargement.35 In a LIFE
substudy, there was a significant correlation between baseline
brachial PP and left atrial size, independent of age, sex, and
body surface area (data not shown).36 Furthermore, there is
much evidence for linking brachial PP to microvascular
damage in the heart and other target organs, which, again,
may lead to increased peripheral resistance and MAP, further
increasing arterial stiffness and central PP. Increased central
PP may then further damage small arteries and lead to LVH.37
Studies have found brachial PP to be a powerful predictor of
cardiovascular morbidity and mortality,38–45 and the predic-
tive effect increases with age.42–44 The present study evalu-
ated brachial PP and not central PP. Noninvasive central PP
has been shown to better predict cardiovascular outcomes
than brachial PP and to be closer associated with extent of
atherosclerosis (carotid plaque burden and intimal-medial
thickness, and vascular mass).46
Table 2. Cox Proportional Hazards Models for PP and other BP Components as Independent
Predictors of New-Onset AF in Patients With Hypertension and ECG-LVH
Multivariate
Model
2 Log Likelihood
for Model
BP Components
in Model*
HR (95% CI) per
10 mm Hg Increase
HR (95% CI) per
1 SD Increase P Value
Model 1 5762.0 Baseline PP 1.14 (1.06–1.23) 1.23 (1.09–1.38) 0.001
Model 2 5739.6 Baseline PP 1.24 (1.14–1.34) 1.39 (1.22–1.58) 0.001
In-treatment PP 1.20 (1.11–1.30) 1.33 (1.18–1.50) 0.001
Model 3 5764.5 Baseline SBP 1.13 (1.04–1.23) 1.20 (1.06–1.34) 0.003
Model 4 5750.2 Baseline SBP 1.18 (1.08–1.28) 1.27 (1.12–1.43) 0.001
In-treatment SBP 1.13 (1.06–1.20) 1.19 (1.09–1.31) 0.001
Model 5 5772.7 Baseline DBP 0.94 (0.84–1.07) 0.95 (0.86–1.06) 0.35
Model 6 5772.6 Baseline DBP 0.95 (0.84–1.08) 0.96 (0.85–1.07) 0.45
In-treatment DBP 1.02 (0.90–1.15) 1.02 (0.91–1.13) 0.77
Model 7 5772.6 Baseline MAP 1.07 (0.94–1.22) 1.06 (0.95–1.18) 0.33
Model 8 5767.4 Baseline MAP 1.11 (0.97–1.27) 1.09 (0.97–1.22) 0.14
In-treatment MAP 1.13 (1.02–1.25) 1.10 (1.01–1.20) 0.02
Model 9 5739.4 Baseline SBP 1.24 (1.14–1.36) 1.36 (1.20–1.55) 0.001
In-treatment SBP 1.20 (1.11–1.30) 1.30 (1.17–1.46) 0.001
Baseline DBP 0.81 (0.71–0.93) 0.83 (0.74–0.94) 0.003
In-treatment DBP 0.82 (0.70–0.95) 0.84 (0.73–0.95) 0.007
Model 10 5739.4 Baseline PP 1.24 (1.14–1.35) 1.39 (1.22–1.59) 0.001
In-treatment PP 1.21 (1.11–1.33) 1.35 (1.17–1.55) 0.001
Baseline MAP 1.01 (0.88–1.16) 1.01 (0.90–1.13) 0.93
In-treatment MAP 0.98 (0.87–1.11) 0.99 (0.89–1.09) 0.77
*All models are adjusted for baseline age, height, weight, and Framingham Risk Score; sex, race, and treatment
allocation; and in-treatment heart rate and ECG-LVH by Cornell product. One SD of the baseline mean was 15.5
mm Hg for PP, 14.3 mm Hg for SBP, 8.8 mm Hg for DBP, and 8.1 mm Hg for MAP.
PP indicates pulse pressure; BP, blood pressure; AF, atrial fibrillation; ECG-LVH, electrocardiographic left ventricular
hypertrophy; HR, hazard ratio; CI, confidence interval; SD, standard deviation; SBP, systolic blood pressure; DBP,
diastolic blood pressure; MAP, mean arterial pressure.
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In conclusion, in patients with hypertension and ECG-LVH
in the LIFE study, increased baseline and in-treatment PP
were independently associated with increased risk of new-
onset AF. PP was (in comparison with SBP, DBP, and MAP)
the single BP component with the strongest predictive effect.
Limitations
Patients evaluated in the LIFE study were predominantly
white and from Western countries. They had hypertension
and ECG-LVH and increased risk of cardiovascular events
compared with hypertensive subjects without LVH. The
results may not be generalizable to normotensives and hyper-
tensives without LVH. BP was measured with a sphygmo-
manometer, which is considered less accurate than 24-hour
ambulatory BP measurement.43 New-onset AF was a pre-
specified secondary end point; however, the LIFE study was
designed and had statistical power for the primary composite
end point, and the HRs for AF require careful interpretation.
Perspectives
In patients with hypertension and ECG-LVH in the LIFE
study, increased baseline and in-treatment PP were indepen-
dently associated with new-onset AF. PP was (in comparison
with SBP, DBP and MAP) the single BP component with the
strongest predictive effect, supporting the hypothesis that the
relation between BP and incident AF is related specifically to
the pulsatile component of BP as assessed by PP.13 Further-
more, SBP and DBP together had a predictive effect similar
to the predictive effect of PP, reflecting the definition of PP.
In-treatment MAP was significantly associated with new-
onset AF when adjusted for baseline MAP and the mentioned
risk factors; however, the predictive effect was weaker than
for PP or for SBP and DBP evaluated together. This result
may imply that the association between MAP (the steady
component of BP) and AF is weak. When evaluating risk of
AF in patients with hypertension and ECG-LVH, both base-
line PP and PP during antihypertensive treatment, alterna-
tively SBP and DBP together, should be considered. Further-
more, lowering of PP may prevent new-onset AF in patients
with hypertension and LVH; however, this must be further
explored in randomized clinical trials.
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Novelty and Significance
What Is New?
● To our knowledge, this is the first study to report a strong, independent
association between baseline pulse pressure and pulse pressure during
antihypertensive treatment and new-onset atrial fibrillation in patients
with hypertension and left ventricular hypertrophy.
What Is Relevant?
● In 8810 patients in this randomized (losartan versus atenolol) treatment
trial, pulse pressure (the pulsatile component of blood pressure and a
marker of arterial stiffness) was the strongest single blood pressure
predictor for atrial fibrillation compared with systolic blood pressure,
diastolic blood pressure, and mean arterial pressure.
Summary
When evaluating risk of atrial fibrillation in patients with hyperten-
sion and left ventricular hypertrophy, both baseline pulse pressure
and pulse pressure during antihypertensive treatment should be
considered.
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Expanded Methods: 
 
Study Design and Population 
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, as described in 
detail elsewhere (1-3), enrolled 9193 patients aged 55 through 80 years (mean 67 years) with 
essential hypertension (mean sitting brachial blood pressure (BP) in the range of 160 to 200 mm 
Hg systolic, 95 to 115 mm Hg diastolic, or both after placebo run-in) having ECG-LVH 
determined by Cornell voltage-duration product (4;5) and/or Sokolow-Lyon voltage criteria (6) 
on a screening ECG in a prospective, double-blind, parallel group study with randomization to 
losartan- vs. atenolol-based therapy targeting a BP of 140/90 mm Hg or lower (1). Patients were 
followed for mean 4.8 years and the main outcome was the composite of cardiovascular death, 
non-fatal stroke and non-fatal myocardial infarction. New-onset atrial fibrillation was a pre-
specified secondary endpoint. 
 BP was measured at follow-up examinations; in the present study we have used yearly 
recordings. After patients had been seated for 5 minutes, BP was measured as the average of two 
recordings with a 1 minute interval with the arm positioned so that the location of the 
stethoscope head was at the level of the heart. 
The trial protocol was approved by all ethics committees concerned, in accordance with 
the Declaration of Helsinki, and was overseen by an independent data and safety monitoring 
board. All participants provided written informed consent. 
A total of 362 patients with a history of AF and/or AF on their baseline ECG and 21 
patients with missing baseline PP were excluded from the present analyses. 
 
Electrocardiography 
Electrocardiograms were obtained at study baseline, at 6 months, and at yearly follow-up 
intervals until study termination or patient death. All ECGs were interpreted at the core 
laboratory at Sahlgrenska University Hospital/Östra, Göteborg, Sweden, by experienced readers 
blinded to clinical information. The QRS durations were measured to the nearest 4 msec and the 
QRS amplitudes to the nearest 0.5 mm (0.05 mV). Cornell product higher than 2440 mm × msec 
(4;5) and/or Sokolow-Lyon voltage higher than 38 mm (6) were used to identify LVH (7;8). 
 
Statistical Analyses 
Serum glucose, serum creatinine and urine albumin-creatinine ratio were log10 or reciprocally 
transformed owing to skewed distributions. 
 In the primary analyses, possible associations between baseline PP or PP during 
antihypertensive therapy and the risk of developing new-onset AF were analyzed according to a 
pre-specified statistical analysis plan using Cox proportional hazards regression analyses (7;9) 
and based on the intention-to-treat principle (3). 
Interaction analyses were performed using Cox regression models with two and two 
covariates (either between a BP component and an adjustment covariate, between two 
adjustment covariates or between two BP components included in the same model) and their 
cross-products (interaction terms). Significant interaction terms were then entered into separate 
Cox regression models that included all the covariates in the multivariate model. 
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Table S1. Baseline Characteristics by Quartiles of Baseline Pulse Pressure (n= 8810)* 
Characteristics 
Q1 (≤67.0 mm Hg) 
n=2334 
Q2 (67.5-77.0 mm Hg) 
n=2189 
Q3 (77.5-87.0 mm Hg)
n=2139 
Q4 (≥87.5 mm Hg) 
n=2148 P  
Male gender, n (%)   1234 (53) 1019 (47) 928 (43) 833 (39) ‡ 
Age, y  64±7  66±7  68±7  70±6  † 
Caucasian ethnicity, n (%)   2115 (91) 2016 (92) 1998 (93) 2013 (94) ‡ 
Weight, kg  81±15  79±15  78±16  76±14  † 
Height, cm  169±10  168±9  167±9  166±9  † 
Body mass index, kg/m2  28.2±4.7  28.0±4.8  28.2±5.1  27.7±4.6  † 
Current smoker, n (%)   391 (17) 378 (17) 347 (16) 324 (15) ns
No exercise, n (%)   464 (20) 429 (20) 502 (24) 531 (25) ‡ 
History of diabetes, n (%)   213 (9) 235 (11) 296 (14) 359 (17) ‡
History of CHD, n (%)   268 (12) 293 (13) 276 (13) 322 (15) ‡
History of heart failure, n (%)   27 (1.2) 31 (1.4) 37 (1.7) 33 (1.5) ns 
Isolated systolic hypertension, n (%)  0 (0) 121 (6) 406 (19) 721 (34) ‡ 
Systolic blood pressure, mm Hg  159±10  171±7  179±9  189±10  † 
Diastolic blood pressure, mm Hg  102±6  99±7  97±9  93±10  † 
Pulse pressure, mm Hg  57±8  72±3  82±3  96±7  na 
Mean arterial pressure, mm Hg 121±6 123±7 125±9 125±9 † 
Heart rate, bpm  75±11  74±11  74±11  73±11  † 
Sokolow-Lyon voltage, mm   28.4±9.9  29.7±10.1  30.2±10.5  31.7±10.7  † 
Cornell product, mm x msec  2738±910  2828±1093  2849±1037  2851±1021  † 
Serum glucose, mmol/L 5.86±2.03 5.88±1.98 6.08±2.31 6.21±2.37 † 
Serum creatinine, µmol/L 87.4±19.1 86.2±18.8 86.2±21.3 86.6±21.1 † 
Total cholesterol, mmol/L 5.99±1.13 6.06±1.10 6.09±1.12 6.09±1.13 † 
HDL cholesterol, mmol/L 1.48±0.44 1.50±0.43 1.50±0.44 1.51±0.44 ns 
Serum uric acid, µmol/L 336±79 329±76 326±77 324±78 † 
UACR, mg/mmol 5.7±30.7 5.6±20.7 7.3±29.1 9.8±35.5 † 
Hemoglobin, mmol/L 144.4±11.8 142.8±11.5 141.9±12.2 140.1±12.0 † 
Framingham Risk Score  20±8  22±9  23±10  25±10  † 
*Values are mean±SD or numbers (n) and percentages. †P <0.01 (ANOVA). ‡P <0.01 (Pearson Chi-Square). CHD indicates coronary heart 
disease; ns, not significant; na, not applicable; bpm, beats per minute; HDL, high density lipoprotein; UACR, urine albumin-creatinine ratio. 
Table S2. Cox Proportional Hazards Model for Baseline PP and In-Treatment PP as 
Independent Predictors of New-Onset AF in Patients with Hypertension and ECG-LVH 
Variable in Multivariate Model χ2 Hazard Ratio (95% CI) P Value 
Baseline pulse pressure per 15.5 mm Hg (1 SD) 25.3 1.39 (1.22 - 1.58) <0.001 
In-treatment pulse pressure per 15.5 mm Hg (1 SD) 21.7 1.33 (1.18 - 1.50) <0.001 
In-treatment Cornell product per 1050 mm x msec (1 SD) 8.3 1.13 (1.04 - 1.23) <0.001 
In-treatment heart rate (bpm) 70.9 1.03 (1.02 - 1.04) <0.001 
Treatment (atenolol vs. losartan) 27.4 1.79 (1.44 - 2.23) <0.001 
Age (y) 103.1 1.10 (1.08 - 1.12) <0.001 
Male gender 1.3 1.23 (0.85 - 1.85) 0.25 
Weight (kg) 17.0 1.02 (1.01 - 1.02) <0.001 
Height (cm) 13.2 1.03 (1.02 - 1.05) <0.001 
Race (white vs. black) 8.2 3.26 (1.45 - 7.35) 0.004 
Framingham Risk Score 7.7 0.98 (0.96 - 0.99) 0.005 
PP indicates pulse pressure; AF, atrial fibrillation; ECG-LVH, electrocardiographic left ventricular hypertrophy; χ2, Chi-Square 
(Wald Score); CI, confidence interval; SD, standard deviation; bpm, beats per minute. 
 
